Skip to content
Life Sciences Seed Founded 2021

Engimmune Therapeutics

Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases

📍 Basel, Switzerland · Oncology

Funding snapshot

Last roundSeed
Amount$16M
Date3 May 2022

About

Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases. The company has proprietary technologies combining genome editing, functional high-throughput screening, deep sequencing, and machine learning to address T-cell receptor therapies for the treatment of cancer. Also, it is expanding its pipeline to treat autoimmune diseases.

Latest news

No articles yet.

Raising like Engimmune Therapeutics?

Analyze your pitch deck before your next raise.

Analyze My Deck →